Regulus pres./R&D head Klassen buys 12,000 shares at $7.99; holds 48,055 post-transaction; company recorded $-9.6M net income and zero revenue last quarter.
Klassen Preston, as President and Head of R&D, purchased 12,000 shares at $7.99, increasing his holdings by 33.3% to 48,055 shares total. The transaction occurs in a company with severe operational distress: Regulus reported zero revenue in its latest quarter and a net income of $-9,634,000.00 for its most recent full fiscal year, reflecting a -100.0% annual revenue decline year-over-year. At $7.95 current price, the stock trades near its 52-week high of $7.98, having recovered substantially from its 52-week low of $0.97 (a 90-day gain of +480.3%), yet the company remains unprofitable with no current revenue generation. This insider acquisition at peak recent valuation amid deteriorating fundamentals presents a factual tension between the open-market buy signal and the underlying business condition; investors should examine what operational developments or clinical/product catalysts justified this accumulation in a pre-revenue stage.